The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive impact of RNF43 mutation (mut) in patients (pts) with pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) treated with target therapy (TT) or chemotherapy (CT).
 
Marco Maria Germani
No Relationships to Disclose
 
Roberto Moretto
No Relationships to Disclose
 
Javier Ros Montañá
Honoraria - Amgen
Speakers' Bureau - Sanofi
Travel, Accommodations, Expenses - Amgen; Amgen; Merck; Pierre Fabre; SERVIER
 
Rossana Intini
No Relationships to Disclose
 
Filippo Ghelardi
No Relationships to Disclose
 
Guglielmo Vetere
No Relationships to Disclose
 
Rodrigo De Almeida Toledo
Research Funding - AstraZeneca; BeiGene; Novartis
 
Francesca Bergamo
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; SERVIER
Speakers' Bureau - Bayer; Eisai; Lilly; MSD Oncology
 
Giovanni Randon
No Relationships to Disclose
 
Elena Elez
Honoraria - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche; Sanofi/Aventis; Seagan; SERVIER
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Bristol Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); Genentech (Inst); HalioDx (Inst); Hutchison MediPharma (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
 
Sara Lonardi
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Incyte; Lilly; Merck Serono; Mirati Therapeutics; MSD; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Simone Oldani
No Relationships to Disclose
 
Mirella Giordano
No Relationships to Disclose
 
Daniele Rossini
Speakers' Bureau - MSD Oncology
 
Walter Ferrari Bravo
No Relationships to Disclose
 
Gianmarco Ricagno
No Relationships to Disclose
 
Paola Vignali
No Relationships to Disclose
 
Clara Ugolini
No Relationships to Disclose
 
Gabriella Fontanini
No Relationships to Disclose
 
Chiara Cremolini
Honoraria - Amgen; Bayer; Merck; Merck; MSD; Pierre Fabre; Roche; SERVIER
Consulting or Advisory Role - Amgen; Bayer; MSD; Nordic Bioscience; Pierre Fabre; Roche
Speakers' Bureau - Merck; Pierre Fabre; SERVIER
Research Funding - Bayer; Merck; Roche; SERVIER